Vandetanib

Key Product Details

Product Description

Vandetanib is a potent VEGFR-2 inhibitor (IC₅₀ = 0.04 μM), and inhibitor of EGFR (IC₅₀ = 0.5 μM). Vandetanib potently inhibits (IC₅₀ = 100 nM) RET oncoprotein activity in human thyroid cancer. Vandetanib displays anti-angiogenic properties in human nasopharyngeal carcinoma in mice model. Vandetanib is orally available and effective in vivo.

Product Specifications for Vandetanib

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Vandetanib

The following data is based on the product molecular weight 475.36.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	4.21 mL	21.04 mL	42.07 mL
2.5 mM	0.84 mL	4.21 mL	8.41 mL
5 mM	0.42 mL	2.10 mL	4.21 mL
25 mM	0.08 mL	0.42 mL	0.84 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 3 publications citing the usage of this product.

• Hennequin Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J.Med.Chem. 2002 PMID: 11881999
• Cui Resonance imaging for monitoring the early response to ZD6474 from nasopharyngeal carcinoma in nude mouse. Sci.Rep. 2015 PMID: 26574153
• Ancker Multikinase inhibitor treatment in thyroid cancer. Int.J.Mol.Sci. 2019 PMID: 31861373
• Carlomagno ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer res. 2002 PMID: 12499271

Product Documents for Vandetanib